论文部分内容阅读
为了观察乙型肝炎病毒携带者妇女口服避孕药对肝功能的影响,本研究选择乙型肝炎表面抗原阳性、肝功能正常、抗HBc—IgM阴性的育龄妇女作为观察对象,非随机分为两组,一组口服低剂量复合避孕药,一组不应用激素类避孕措施,随访观察半年。共159例妇女完成了随访观察,服药组78例,对照组81例。随访期间,两组均未出现肝炎的症状和体征,第3个月和第6个月时取血检查GPT、白蛋白、胆红素和凝血酶原时间,两组没有显著性差异,P>0.05。第3个月检查时,服药组有1例GPT值高于正常,第6个月检查时正常。根据初步观察,乙型肝炎表面抗原阳性妇女口服避孕药对肝功能没有明显影响,但是仍有必要扩大样本进一步观察,并且在人群中注意不良反应的监测。
In order to observe the effects of oral contraceptives on liver function in hepatitis B virus carriers, we selected women of childbearing age who were positive for hepatitis B surface antigen (HBsAg), normal liver function, anti-HBc-IgM, and were randomly divided into two groups , A group of low-dose oral contraceptives, a group of hormonal contraception should not be used, followed up for six months. A total of 159 women completed the follow-up observation, 78 cases in the medication group and 81 cases in the control group. No symptoms and signs of hepatitis were observed in the two groups during the follow-up period. GPT, albumin, bilirubin and prothrombin time were taken at the third month and the sixth month, there was no significant difference between the two groups (P> 0.05. At the third month of examination, one patient in the medication group had a GPT higher than normal and a normal one at the 6th month. According to a preliminary observation, oral contraceptives of women with hepatitis B surface antigen have no significant effect on liver function, but it is still necessary to expand the sample for further observation, and pay attention to the monitoring of adverse reactions in the crowd.